Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
| Active as of 2023-12-17 |
<Evidence xmlns="http://hl7.org/fhir">
<id value="179635"/>
<meta>
<versionId value="4"/>
<lastUpdated value="2023-12-03T09:56:07.995Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Evidence</b><a name="179635"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Evidence "179635" Version "4" Updated "2023-12-03 09:56:07+0000" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparative-participant-flow.html">ComparativeParticipantFlow</a></p></div><p><b>StructureDefinition Work Group</b>: cds</p><p><b>url</b>: <code>https://fevir.net/resources/Evidence/179635</code></p><p><b>identifier</b>: FEvIR Object Identifier: 179635</p><p><b>version</b>: 1.0.0-ballot</p><p><b>name</b>: ComparativeParticipantFlow_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial</p><p><b>title</b>: ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial</p><p><b>status</b>: active</p><p><b>date</b>: 2023-12-17 16:55:23+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>author</b>: Brian S. Alper: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td>Evidence Communication (Details: https://fevir.net/resources/CodeSystem/179423 code evidence-communication = 'Evidence Communication', stated as 'Evidence Communication')</td><td>ComparativeParticipantFlow <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-179423.html">Evidence Based Medicine on FHIR Implementation Guide Code System</a>#ComparativeParticipantFlow)</span></td></tr></table><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Citation</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>cite-as</td><td>ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Evidence]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2023-11-27. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635.</td><td> </td></tr><tr><td style="display: none">*</td><td>derived-from</td><td> </td><td><a href="Citation-179637.html">Citation/179637: 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal</a></td></tr></table><p><b>description</b>: Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial</p><blockquote><p><b>variableDefinition</b></p><p><b>VariableDefinitionVariableRoleCode</b>: population</p><p><b>description</b>: Participants in the opioid detoxification trial</p><p><b>note</b>: population</p><p><b>variableRole</b>: Use extension:variableRoleCode instead. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-variable-role.html">EvidenceVariableRole</a>#population "population")</span></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>VariableDefinitionVariableRoleCode</b>: exposure</p><p><b>VariableDefinitionComparatorCategory</b>: false</p><p><b>description</b>: GroupAssignment: Lofexidine vs. Placebo</p><p><b>note</b>: exposure</p><p><b>variableRole</b>: Use extension:variableRoleCode instead. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-variable-role.html">EvidenceVariableRole</a>#exposure "exposure")</span></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>VariableDefinitionVariableRoleCode</b>: outcome</p><p><b>description</b>: Dropout due to stopping intervention</p><p><b>note</b>: outcome</p><p><b>variableRole</b>: Use extension:variableRoleCode instead. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-variable-role.html">EvidenceVariableRole</a>#measuredVariable "measured variable")</span></p><p><b>observed</b>: <a href="EvidenceVariable-179636.html">EvidenceVariable/179636: PartiicipantFlowMeasure: Dropout due to stopping intervention</a> "ParticipantFlowMeasure_Dropout_due_to_stopping_intervention"</p></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: 18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)</p><p><b>statisticType</b>: Risk Ratio <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-181513.html">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#STATO:0000245)</span></p><p><b>quantity</b>: 1.59</p><p><b>numberAffected</b>: 30</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>NumberOfParticipants</b></td></tr><tr><td style="display: none">*</td><td>68</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Description</b></td><td><b>Type</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td>p < 0.01</td><td>P-value <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-181513.html">Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide</a>#TBD:0000076)</span></td><td><0.01</td></tr></table></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
<valueCode value="cds"/>
</extension>
<url value="https://fevir.net/resources/Evidence/179635"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179635"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<version value="1.0.0-ballot"/>
<name
value="ComparativeParticipantFlow_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial"/>
<title
value="ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial"/>
<status value="active"/>
<date value="2023-12-17T16:55:23+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<author>
<name value="Brian S. Alper"/>
</author>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="ComparativeParticipantFlow"/>
<display value="ComparativeParticipantFlow"/>
</coding>
</valueCodeableConcept>
</useContext>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<relatedArtifact>
<type value="cite-as"/>
<citation
value="ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Evidence]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2023-11-27. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635."/>
</relatedArtifact>
<relatedArtifact>
<type value="derived-from"/>
<resourceReference>🔗
<reference value="Citation/179637"/>
<type value="Citation"/>
<display
value="18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"/>
</resourceReference>
</relatedArtifact>
<description
value="Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial"/>
<variableDefinition>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
<valueCode value="population"/>
</extension>
<description value="Participants in the opioid detoxification trial"/>
<note>
<text value="population"/>
</note>
<variableRole>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/variable-role"/>
<code value="population"/>
<display value="population"/>
</coding>
<text value="Use extension:variableRoleCode instead."/>
</variableRole>
</variableDefinition>
<variableDefinition>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
<valueCode value="exposure"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category">
<valueString value="false"/>
</extension>
<description value="GroupAssignment: Lofexidine vs. Placebo"/>
<note>
<text value="exposure"/>
</note>
<variableRole>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/variable-role"/>
<code value="exposure"/>
<display value="exposure"/>
</coding>
<text value="Use extension:variableRoleCode instead."/>
</variableRole>
</variableDefinition>
<variableDefinition>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
<valueCode value="outcome"/>
</extension>
<description value="Dropout due to stopping intervention"/>
<note>
<text value="outcome"/>
</note>
<variableRole>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/variable-role"/>
<code value="measuredVariable"/>
<display value="measured variable"/>
</coding>
<text value="Use extension:variableRoleCode instead."/>
</variableRole>
<observed>🔗
<reference value="EvidenceVariable/179636"/>
<type value="EvidenceVariable"/>
<display
value="PartiicipantFlowMeasure: Dropout due to stopping intervention"/>
</observed>
</variableDefinition>
<statistic>
<description
value="18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)"/>
<statisticType>
<coding>
<system value="https://fevir.net/resources/CodeSystem/181513"/>
<code value="STATO:0000245"/>
<display value="Risk Ratio"/>
</coding>
</statisticType>
<quantity>
<value value="1.59"/>
</quantity>
<numberAffected value="30"/>
<sampleSize>
<numberOfParticipants value="68"/>
</sampleSize>
<attributeEstimate>
<description value="p < 0.01"/>
<type>
<coding>
<system value="https://fevir.net/resources/CodeSystem/181513"/>
<code value="TBD:0000076"/>
<display value="P-value"/>
</coding>
</type>
<quantity>
<value value="0.01"/>
<comparator value="<"/>
</quantity>
</attributeEstimate>
</statistic>
</Evidence>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change